Brookfield Asset Management Inc. Amicus Therapeutics, Inc. Transaction History

Brookfield Asset Management Inc.

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	SELL	$9.82 - $12.75 $3.96 Million - $5.14 Million	-403,249 Reduced 78.3%	111,751 $1.17 Million
Q2 2022 Nov 16, 2022	BUY	$6.23 - $11.12 $2.51 Million - $4.48 Million	403,249 Added 360.85%	515,000 $5.53 Million
Q2 2022 Aug 15, 2022	SELL	$6.23 - $11.12 $591,850 - $1.06 Million	-95,000 Reduced 15.57%	515,000 $5.53 Million
Q1 2022 May 16, 2022	SELL	$7.89 - $12.48 $1.5 Million - $2.37 Million	-190,000 Reduced 23.75%	610,000 $5.78 Million
Q4 2021 Feb 14, 2022	SELL	$9.82 - $12.44 $441,900 - $559,800	-45,000 Reduced 5.33%	800,000 $9.24 Million
Q3 2021 Nov 16, 2021	BUY	$8.74 - $11.84 $3.07 Million - $4.15 Million	350,822 Added 70.99%	845,000 $8.07 Million
Q2 2021 Aug 17, 2021	BUY	$8.71 - $10.72 $126,295 - $155,440	14,500 Added 3.02%	494,178 $4.76 Million
Q1 2021 May 17, 2021	BUY	$9.2 - $23.86 $4.41 Million - $11.4 Million	479,678 New	479,678 $4.74 Million

312

312M

516K

833K

Ticker FOLD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 280,497,984
Market Cap $2.68B
Description
Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant bas...

Get notified when there are updates to the investment portfolio of Brookfield Asset Management Inc., based on Form 13F filings with the SEC.

Stay updated on Brookfield Asset Management Inc. with notifications on news.